Thus, TRPML1 overexpression has been found in cancer-bearing, oncogenic HRAS mutations [10], triple-negative breast cancer (TNBC) cell lines [11], melanomas [12], non-small-cell lung carcinomas (NSCLCs) [13], pancreatic adenocarcinomas (PDACs) [14] and p53-deficient bladder cancer [15]. This evidence concerns the gene MCOLN1 and urinary bladder carcinoma.